Renal Manifestations of Systemic Illness in Children

Seminars in Nephrology

Volumn 29, Issue 4, 2009, Pages 360-369

  Gibson, Keisha L ^a   Gipson, Debbie S ^a   Massengill, Susan F ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

nephritogenic; tubulointerstitial disease; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; CIMETIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; ISONIAZID; LANSOPRAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PLACEBO; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ARTICLE; ATHEROSCLEROSIS; BK VIRUS; CHILD; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HEMOLYTIC UREMIC SYNDROME; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY SCAR; KIDNEY TUBULE NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PYURIA; REMISSION; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

CHILD; CHILD, PRESCHOOL; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TUBULES; NEPHRITIS; THROMBOSIS; VASCULITIS;

EID: 67650263760     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.03.012     Document Type: Article

References (75)

1. Jennette J.C., Falk R.J., Adrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
2. Fries J.F., Hunder G.G., Bloch D.A., Michel B.A., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33 (1990) 1135-1136
3. Pinna G.S., Kafetzis D.A., Tselkas O.I., and Skevaki C.L. Kawasaki disease: an overview. Curr Opin Infect Dis 21 (2008) 263-270
4. Oates-Whitehead R.M., Baumer J.H., Haines L., Love S., Maconochie I.K., Gupta A., et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4 (2003) CD004000
5. Baumer J.H., Love S.J., Gupta A., Haines L., Maconochie I.K., and Dua J.S. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4 (2006) CD004175
6. Watanabe T., Abe Y., Sato S., Uehara Y., Ikeno K., and Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and kidney. Pediatr Nephrol 22 (2007) 987-991
7. El Karoui K., Servais A., Fadel F., Jablonski M., Fakhouri F., Lesavre P., et al. Acute renal failure and febrile rash-infectious or not?. Adult Kawasaki disease. Nephrol Dial Transplant 22 (2007) 949-951
8. Wang J.N., Chiou Y.Y., Chiu N.T., Chen M.J., Lee B.F., and Wu J.M. Renal scarring sequelae in childhood Kawasaki disease. Pediatr Nephrol 22 (2007) 684-689
9. Nardi P.M., Haller J.O., Friedman A.P., Slovis T.L., and Schaffer R.M. Renal manifestations of Kawasaki's disease. Pediatr Radiol 15 (1985) 116-118
10. Wyatt R.J., Kritchevsky S.B., Woodford S.Y., Miller P.M., Roy III S., Holland N.H., et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr 127 (1995) 913-919
11. Ronkainen J., Ala-Houhala M., Autio-Harmainen, Jahnukainen T., Koskimies O., Merenmies J., et al. Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 21 (2006) 1266-1273
12. Coppo R., Mazzucco G., Cagnoli L., Lupo A., and Schena F.P. Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. Nephrol Dial Transplant 12 (1997) 2277-2283
13. Weiss P.F., Feinstein J.A., Luan X., Burnham J.M., and Feudtner C. Effects of corticosteroids on Henoch-Schönlein purpura: a systematic review. Pediatrics 120 (2007) 1079-1087
14. Dudley J., Smith G.C., Llewellyn-Edwards A., and Tizard J. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein purpura nephritis [abstract]. J Am Soc Nephrol 18 (2007) 47A
15. Gibson K.L., Amamoo M.A., and Primack W.A. Corticosteroid therapy for Henoch- Schönlein purpura. Pediatrics 121 (2008) 870-871
16. Perfumo F., and Martini A. Lupus nephritis in children. Lupus 14 (2005) 83-88
17. Hagelberg S., Lee Y., Bargman J., Mah G., Schneider R., Laskin C., et al. Longterm followup of childhood lupus nephritis. J Rheumatol 29 (2002) 2635-2642
18. Lee B.S., Cho H.Y., Kim E.J., Kang H.G., Ha I.S., Cheong H.I., et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 22 (2007) 222-231
19. Baqi N., Moazami S., Singh A., Ahmad H., Balachandra S., and Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 7 (1996) 924-929
20. Yang L.Y., Chen W.P., and Lin C.Y. Lupus nephritis in children-a review of 167 patients. Pediatrics 94 (1994) 335-340
21. Austin III H.A., Klippel J.H., Galow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis: controlled study of prednisone and cytotoxic drugs. N Engl J Med 314 (1986) 614-619
22. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
23. Appel G.B., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., Solomons N., et al. Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results. Free communication: late-breaking interventions in glomerular disease and diabetic nephropathy. American Society of Nephrology Renal Week. J Am Soc Nephrol [abstract] 18 (2007) 47A
24. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350 (2004) 971-980
25. Lenz O., Fornoni A., and Contreras G. Defining the role of mycophenolate mofetil in proliferative lupus nephritis. Drugs 65 (2005) 2429-2436
26. Lau K.K., Ault B.H., Jones D.P., and Butani L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 22 (2008) 282-288
27. Fujinaga S., Ohtomo Y., Hara S., Umino D., Someya T., Shimizu T., et al. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol 23 (2008) 1877-1882
28. Clinical trials.gov. A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with ISN/RPS Class III or IV Lupus Nephritis (LUNAR). http//www.clinicaltrials.gov/ct2/show/ NCT00282347?term=lunar&rank=1
29. Podolskaya A., Stadermann M., Pilkington C., Marks S.D., and Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93 (2008) 401-406
30. De Lind Van Winjgaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17 (2006) 2264-2274
31. Westman K.W., Bygren P.G., Olsson H., Ranstam J., and Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9 (1998) 842-852
32. Hogan S.L., Falk R.J., Chin H., Cai J., Jennette C.E., Jennette J.C., et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143 (2005) I22
33. Henke D., Falk R.J., and Gabriel D.A. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 140 (2004) 493-494
34. Klemmer P.J., Chalermskulrat W., Reif M.S., Hogan S.L., Henke D.C., and Falk R.J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42 (2003) 1149-1153
35. Gaskin G., and Pusey C.D. Plasmapheresis in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis. Ther Apher 5 (2001) 176-181
36. Gazarian M., Feldman B.M., Benson L.N., Gilday D.L., Laxer R.M., and Silverman E.D. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosis. J Pediatr 132 (1998) 109-116
37. Karrar A., Sequiera W., and Block J.A. Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 30 (2001) 436-443
38. Kavey R.W., Allada V., Daniels S.R., Hayman L.L., NcCrindle B.W., Newburger J.W., et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. Circulation 114 (2006) 2710-2738
39. Sandborg C., Ardoin S.P., and Schanberg L. Therapy insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol 4 (2008) 258-265
40. Michel D.M., and Kelly C.J. Acute interstitial nephritis. J Am Soc Nephrol 9 (1998) 507-515
41. Neilson E.G. Pathogenesis and therapy of interstitial nephritis. Kidney Int 35 (1989) 1257-1270
42. Joss N., Morris S., Young B., and Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2 (2007) 222-230
43. Gobel U., Kettritz R., Schneider W., and Luft F.C. The protean face of renal sarcoidosis. J Am Soc Nephrol 12 (2001) 616-623
44. Berliner A.R., Haas M., and Choi M.J. Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis 48 (2006) 856-870
45. Rizzato G. Extrapulmonary presentation of sarcoidosis. Curr Opin Pulm Med 7 (2001) 295-297
46. Birnbacher R., Balzar E., Aufricht C., Schmaldienst S., Woloszczuk W., and Forster E. Tubulointerstitial nephritis and uveitis: an immunological disorder?. Pediatr Nephrol 9 (1995) 193-195
47. Herlitz L.C., Chun M.J., Stokes M.B., and Markowitz G.S. Uveitis and acute renal failure. Kidney Int 72 (2007) 1554-1557
48. Izzedine H., Bodaghi B., Launay-Vacher V., and Deray G. Oculorenal manifestations in systemic autoimmune diseases. Am J Kidney Dis 43 (2004) 209-222
49. Eddy A. Experimental insights into the tubulointerstitial disease company primary glomerular lesions. J Am Soc Nephrol 5 (1994) 1273-1287
50. Harris D. Tubulointerstitial renal disease. Curr Opin Nephrol Hypertens 10 (2001) 303-313
51. Meyers C.M. New insights into the pathogenesis of interstitial nephritis. Curr Opin Nephrol Hypertens 8 (1999) 287-292
52. Cavallo T. Tubulointerstitial nephritis. In: Jennette J.C., Olson J.L., Schwartz M.M., and Silva F.G. (Eds). Heptinstall's pathology of the kidney. 5th ed. (1998), Lippincott-Raven Publishers, Philadelphia 667-723
53. Lai A.S.H., and Lai K.N. Viral nephropathy. Nat Clin Pract 2 (2006) 254-262
54. Kimmel P.L., Barisoni L., and Kopp J.B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 139 (2003) 214-226
55. Nickeleit V., Singh H.K., and Mihatsch M.J. Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens 12 (2003) 599-605
56. Smith J.M., McDonald R.A., Finn L.S., Healey P.J., Davis C.L., and Limaye A.P. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transpl 4 (2004) 2109-2117
57. Green M., Avery R.K., and Preiksaitis J. BK virus infection. Am J Transplant 4 Suppl (2004) 89-91
58. Nickeleit V., Steigfer J., and Mihatsch M.J. BK virus infection after kidney transplantation. Graft 5 Suppl (2002) S46-S57
59. Hirsch H.H., Brennan D.C., Drachenberg C.B., Ginevri F., Gordon J., Limaye A.P., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 (2005) 1277-1286
60. Proulz F., and Socket P. Prospective surveillance of Canadian children with the hemolytic uremic syndrome. Pediatr Nephrol 20 (2005) 786-790
61. Gerber A., Karch H., Allerberger F., Verweyen H.M., and Zimmerhackl L.B. Clinical course and the role of Shiga toxin producing Escherichia coli infection in the hemolytic uremic syndrome in pediatric patients, 1997-2000 in Germany and Austria: a prospective study. J Infect Dis 186 (2002) 493-500
62. Verweyen H.M., Karch H., Allerberger F., and Zimmerhackl L.B. Enterohemorrhagic Escherichia coli (EHEC) in pediatric hemolytic uremic syndrome: a prospective study in Germany and Austria. Infection 27 (1999) 341-347
63. Rowe P.C., Orrbine E., Lior H., Wells G.A., Yetisir E., Clulow M., et al. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. J Pediatr 132 (1998) 777-782
64. Scheiring J., Andreoli S.P., and Zimmerhackl L.B. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome. Pediatr Nephrol 23 (2008) 1749-1760
65. Garg A.X., Suri R.S., Barrowman N., Rehman F., Matsell D., Rosas-Arellano M.P., et al. Long term renal prognosis of diarrhea associated hemolytic uremic syndrome. JAMA 290 (2003) 1360-1370
66. Klein P.J., Bulla M., Newman R.A., Muller P., Uhlenbruck G., Schaefer H.E., et al. Thomsen-Friedenreich antigen in haemolytic uraemic syndrome. Lancet 2 (1977) 1024-1025
67. Brandt J., Wong C., Mihm S., Roberts J., Smith J., Brewer E., et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 110 (2002) 371-376
68. Besbas N., Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., et al. European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70 (2006) 423-431
69. Noris M., Ruggenenti P., Perna A., Orisio S., Caprioli J., Skerka C., et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 10 (1999) 281-293
70. Bresin E., Daina E., Noris M., Castelletti, Stafanov R., Hill P., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uremic syndrome. Prognostic significance of genetic background. Clin J Am Soc Nephrol 1 (2006) 88-99
71. Landau D., Shalev H., Levy-Finer G., Polonsky A., Segev Y., and Katchko L. Familial haemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138 (2001) 12-17
72. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predisposes to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100 (2003) 12966-12971
73. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., et al. Familial hemolytic uremic syndrome and an MCP mutation. Lancet 362 (2003) 1542-1547
74. Licht C., Stapenhorst L., Simon T., Budde U., Schneppenheim R., and Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 663 (2004) 955-958
75. Van Hove J.L.K., Van Damme-Lombaerts R., Grunewald S., Peters H., Van Damme B., Fryns J.P., et al. Cobalamin disorder cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 111 (2002) 195-201